Recombinant protein · Protein replacement · developed by Takeda Pharmaceuticals U.S.A.
Vonicog alfa is a recombinant von Willebrand factor administered by intravenous injection for von Willebrand Disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05582993 | Phase 3 | Von Willebrand Disease (VWD) | Recruiting | TAK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Von Willebrand Disease (VWD)
Updated Oct 3, 2026. Something wrong or missing? Report it on the TAK page.
See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TAK catalysts and pipeline →